ALEXANDRIA, Va., March 26 -- United States Patent no. 12,258,385, issued on March 25, was assigned to Janssen Biotech Inc. (Horsham, Pa.).

"CD137 binding fibronectin type III domains" was invented by Michael Diem (Havertown, Pa.), Rebecca Hawkins (Harleysville, Pa.), Steven Jacobs (North Wales, Pa.) and Manuel Sepulveda (Princeton Junction, N.J.).

According to the abstract* released by the U.S. Patent & Trademark Office: "FN3 domains that specifically bind to CD137, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making and using them are useful in therapeutic and diagnostic applications."

The patent was filed on April 28, 2022, under Application No. 17/732,420.

*For further information...